Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2018

Net Loss per Share

Schedule of basic and diluted net loss per share

	Three Months Ended March 31,
	2018			2017
Numerator:
Net loss	$	(85,462	)	$	(18,753	)
Accretion of beneficial conversion feature on Series A preferred shares	—			(4,000		)
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.	$	(85,462	)	$	(22,753	)
Denominator:
Weighted average common shares outstanding—basic and diluted	36,793,090			13,088,861
Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted	$	(2.32	)	$	(1.74	)

Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share

	Three Months Ended March 31,
	2018	2017
Options to purchase common shares	5,979,093	4,345,344
Warrants to purchase common shares	546,751	815,000
	6,525,844	5,160,344